Xcout Intel
GenScript
Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Subscribe to see GenScript’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
GenScript at a glance
GenScript is a biotech company headquartered in China. It is publicly listed (1548.HK) with a market capitalisation of $12.6B. Xcout tracks 9 named people at GenScript, including Allen Guo (CEO of ProBio). Xcout recorded 293 job postings from GenScript in the last 90 days, naming tools such as SAP, Jira, LangGraph.
GenScript leadership
- Allen GuoCEO of ProBio
- Sherry ShaoRotating CEO (on duty) of GenScript BioTech Corp.
- Ray ChenPresident of GenScript Life Science Group
- Phil ZhouChief Financial Officer of GenScript BioTech Corp.
- Aylin Kosova BilginChief Marketing & Corporate Communications Officer
- Kening LiGeneral Counsel and Chief Compliance Officer
3 more named people on record for GenScript, with roles, board committees and tenure — see the full roster →
Hiring at GenScript
Xcout recorded 293 job postings from GenScript in the last 90 days, from a hiring record Xcout has kept since May 2026.
Tools named in GenScript's job postings
The weekly hiring trend, the roles and locations behind it and all 13 tools — see GenScript's hiring signals →
Hiring vs the trend
Based on 113 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 158 scale-up healthcare companies.
This describes a hiring pattern — how often GenScript’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Tech stack
GenScript competitors
A few of GenScript's closest competitors — see the full list of competitors and alternatives →
Healthgen Biotech Co., Ltd. is a Chinese biotechnology company that develops plant-based recombinant proteins using molecular-farming technologies, notably recombinant human serum albumin produced in rice. It supplies biopharmaceutical and life-science raw materials for applications including cell culture, drug development, and research.
Wuhan Healthgen Biotechnology Corp. develops and manufactures plant-derived recombinant human serum albumin and related biopharmaceutical materials. Its products serve biopharmaceutical manufacturers, including applications in cell culture, drug formulation, vaccines, and diagnostics.
Creative Biolabs is a biotechnology company that provides custom antibody development, engineering, and manufacturing services for pharmaceutical and research projects.
Flash Therapeutics is a French biotechnology company specializing in lentiviral vector technologies and gene-delivery solutions. It serves academic and pharmaceutical/biotechnology researchers, including through development and GMP manufacturing services for gene-therapy applications.
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutions, with operations spanning the United States, Europe, and other international markets. Their comprehensive offerings encompass research kits, bulk enzymes, various other biological products, as well as crucial licensing and AVV manufacturing services. The company primarily caters to clients within the biotech, pharmaceutical, and contract development and manufacturing organization (CDMO) industries. Notably, the firm adopted its current name, 4basebio PLC, in July 2021, having previously been known as 4basebio UK Societas.
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for COVID-19 testing. It also provides contract services related to regenerative medicine products and contract services related to gene analysis and testing. In addition, the company is involved in commercialization of its proprietary platform technology for biologics development; development, manufacture, and sale of manufacture ancillary materials, such as RetroNectin that is used in the manufacture of gene therapy product; application for marketing authorization of NY-ESO-1 siTCR gene therapy product; and development of JAK/STAT technology suitable for CAR gene therapy and applied development of CereAAV, a brain-tropic adeno-associated virus vector. It provides its products and services through sales agents or directly to its customers. The company was incorporated in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
Get GenScript's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on GenScript in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access